ABCL Q1 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-18.4% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$55M-551.5% margin

Net Income

-$41M-408.0% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+8.4%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$66M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$333M

Stockholders' Equity

$1.1B

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$12M	-18.4%
Gross Profit	$10M	$12M	-18.4%
Operating Income	-$55M	-$65M	+15.4%
Net Income	-$41M	-$40M	-1.2%

Revenue Segments

Research Fees

$10M98%

License

$180,0002%